Please assess the completion status of the following clinical trial:

Trial Title: Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* underwent macroscopically curative resection;~* immunohistochemically confirmed KIT (CD117)-positive tumors;~* judged as being high-risk according to the criteria for risk classification~Exclusion Criteria:~* synchronous double cancer or metachronous double cancer with a disease-free period of ≤5 years;~* received therapy with Imatinib Mesylate prior to study entry;~* cardiac problem of Grade 3 or higher (New York Heart Association (NYHA) criteria)~Other protocol-defined inclusion / exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib Mesylate (Type: EXPERIMENTAL): 400 mg once per day

Based on this trial design, predict the completion outcome and termination type (if applicable).